Adipotide
Also known as: FTPP, Prohibitin-targeting peptide
Adipotide is an experimental peptide studied only in preclinical and animal research for effects on fat tissue. It has not been tested or approved for human use.
- Category
- Metabolic / Fat Loss
- Reported half-life
- Not well established
- Common forms
- Research-grade compound used in preclinical studies (not approved)
- Research status
- Investigational peptide with only preclinical and animal data. Not tested in approved human trials and not approved anywhere, including Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in animal research to be investigated for reduction of fat tissue
- Reported to target the blood-vessel supply of fat tissue in preclinical models
- Reported in animal studies to be associated with body-weight changes
How it is reported to work
Adipotide is described as a peptide designed to bind prohibitin on the blood vessels supplying white fat tissue, linked to a pro-apoptotic sequence. In animal models it is proposed to reduce the blood supply to fat, prompting fat-cell loss. These mechanisms are reported only from preclinical research and have not been established in humans.
Background
Adipotide is an experimental peptide studied only in preclinical and animal research for effects on fat tissue. It has not been tested in established human trials and is not approved anywhere. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Adipotide has been reported in animal studies to be of interest for reducing fat tissue, with researchers describing a mechanism targeting the blood supply of fat. These are reported preclinical findings only, not established outcomes in people, and human evidence does not exist.
| Feature | Reported in research |
|---|---|
| Stage | Preclinical / animal only |
| Reported target | Prohibitin on fat-tissue vessels |
| Approval | Not approved anywhere |
What people use it for (reported)
Adipotide is sometimes discussed online in the context of fat loss, but as a compound with only animal data it has no approved use and no established human-use basis. Material described online as “adipotide” is not a verified, approved product, so its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this community.
Things to be aware of
Because adipotide has only animal data, its safety and effects in humans are unknown, and animal research has noted potential kidney effects. The reported effects on this page come from preclinical models and are not confirmed facts in people. Anyone with weight or metabolic concerns should consult a qualified healthcare professional for individualised guidance rather than relying on unapproved compounds. This article is educational, does not recommend any dose, and does not tell anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in animal studies to reduce white fat tissue
- Reported to target the blood-vessel supply of fat in preclinical models
- Reported in animal research to be associated with rapid body-weight reduction
- Reported interest as a novel anti-obesity mechanism in early research
Common side effects
- Increased urination reported in animal studies
- Dehydration reported in preclinical models
- Reduced food intake reported in animals
- Changes in kidney markers reported in animal research
Rare / serious side effects
- Kidney injury reported in animal studies, with possible structural changes
- Unknown human toxicity due to absence of established human trials
- Unverified effects from contaminated grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Adipotide. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported human self-experimentation despite the compound having no established human trials
- Reported use of grey-market product with no verified identity, purity or safe dose
- Reported disregard for documented animal kidney toxicity when self-dosing
- Reported pursuit of rapid weight loss in place of evidence-based medical care
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported effects come only from short animal studies showing weight reduction over a few weeks; no validated human onset exists.
First effects
Reported reduced food intake in animal models within the first week
Noticeable change
Reported body-weight reduction over a short animal dosing course
Clear results
Reported fat-mass loss reported only in animal studies, not humans
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Adipotide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection in animal research only; no established human route |
|---|---|
| Typical reported dose | Reported only as preclinical dosing scaled by body weight in animal studies (for example, doses on the order of 0.43 mg per kg reported in primate research). No established human dosing exists. |
| Frequency | Reported as short daily dosing courses in animal studies only |
| Cycle length | Reported animal courses lasted a few weeks; no validated human cycle exists |
No human cycle is established; animal research reportedly used short daily dosing courses. Reported information from preclinical studies only, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported discussed together as experimental fat-loss compounds
Reported grouped with other fat-targeting research peptides
Reported mentioned alongside fat-reduction-focused compounds
Safety notes
Adipotide has only been studied in animals and has not undergone established human trials; animal research has noted potential kidney effects. Its safety in humans is unknown, and it is not an approved medicine in Australia. Anyone with weight or metabolic questions should consult a qualified healthcare professional rather than relying on unapproved compounds.